About Platelet-activating factor receptor
Platelet-activating factor receptor (PTAFR) is a protein
from Homo sapiens identified by UniProt accession
P25105, 342 residues long.
MolForge cross-references it against 0 known binders and
218 disease associations.
Target properties
| Protein name | Platelet-activating factor receptor |
|---|
| UniProt accession | P25105 |
|---|
| Gene | PTAFR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 342 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (218)
Diseases linked to this target (Open Targets).
- allergic disease · score 0.46
- allergic rhinitis · score 0.37
- urticaria · score 0.33
- rheumatoid arthritis · score 0.26
- glioblastoma multiforme · score 0.25
- breast adenocarcinoma · score 0.24
- inflammatory bowel disease · score 0.15
- neoplasm · score 0.11
- chronic obstructive pulmonary disease · score 0.10
- melanoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P25105-F1 | alphafold | PREDICTED | 86.50 | — |
Amino-acid sequence (342 residues)
MEPHDSSHMD SEFRYTLFPI VYSIIFVLGV IANGYVLWVF ARLYPCKKFN EIKIFMVNLT MADMLFLITL PLWIVYYQNQ GNWILPKFLC NVAGCLFFIN TYCSVAFLGV ITYNRFQAVT RPIKTAQANT RKRGISLSLV IWVAIVGAAS YFLILDSTNT VPDSAGSGNV TRCFEHYEKG SVPVLIIHIF IVFSFFLVFL IILFCNLVII RTLLMQPVQQ QRNAEVKRRA LWMVCTVLAV FIICFVPHHV VQLPWTLAEL GFQDSKFHQA INDAHQVTLC LLSTNCVLDP VIYCFLTKKF RKHLTEKFYS MRSSRKCSRA TTDTVTEVVV PFNQIPGNSL KN
Explore Platelet-activating factor receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets